Comparative Treatment Outcomes Across Actionable Genomic Alterations in NSCLC: A Large Multicenter Real-World Study [0.03%]
基于大型多中心真实世界研究的NSCLC可行动基因组改变治疗结局的比较分析
Yasuhiro Kato,Nobuhiko Nishijima,Satoshi Takahashi et al.
Yasuhiro Kato et al.
Introduction: Although the efficacy of molecular targeted therapies varies across actionable genomic alterations in NSCLC, comparisons within a single real-world cohort remain limited. ...
Gene Expression Clustering of Lung Adenocarcinoma Tumors as a Prognosis Tool to Infer Progression-Free Survival [0.03%]
基于基因表达谱的肺腺癌肿瘤无进展生存期预后分子分型及其免疫特征研究
Sébastien Renaut,Victoria Saavedra Armero,Dominique K Boudreau et al.
Sébastien Renaut et al.
Introduction: Lung cancer is the leading cause of cancer-related death. Studies have reported distinct tumor type based on gene expression signatures and attempted to use this information to predict survival, with limited...
Development and Characterization of a Patient-Derived KIF5B-RET Fusion Lung Adenocarcinoma Cell Line for Subcutaneous and Central Nervous System Tumor Models in Immunodeficient Mice [0.03%]
一种用于免疫缺陷小鼠皮下和中枢神经系统肿瘤模型的KIF5B-RET融合肺腺癌细胞系的开发与表征
Akihiro Nishiyama,Shigeki Sato,Hiroyuki Sakaguchi et al.
Akihiro Nishiyama et al.
Introduction: This study presents the development and characterization of a novel lung adenocarcinoma cell line with kinesin family member 5B rearranged during transfection (KIF5B-RET) fusion, derived from a single patien...
Clinical Activity of RET TKI Plus Chemotherapy After Progression on a RET TKI in a RET Fusion-Positive NSCLC Real-World Cohort: A Brief Report [0.03%]
RET融合阳性NSCLC真实世界队列中选择性RET TKI进展后联合化疗的临床疗效：简短报告
Alvaro Guimaraes Paula,Ximeng Liu,Amirali Karimi et al.
Alvaro Guimaraes Paula et al.
Introduction: RET fusion-driven NSCLC accounts for 2% of advanced lung adenocarcinomas, and selective RET tyrosine kinase inhibitors (RETis) are the current first-line standard-of-care treatment. However, acquired resista...
Continued Cemiplimab Beyond Progression With Addition of Chemotherapy in Patients With Advanced NSCLC With PD-L1 Expression of 50% or Higher: 5-Year Follow-Up From EMPOWER-Lung 1 [0.03%]
恩沃利单抗进展后联合化疗治疗PD-L1表达≥50%的晚期非小细胞肺癌患者：EMPOWER-Lung 1研究5年随访结果
Marina Chiara Garassino,Ana Baramidze,Saadettin Kilickap et al.
Marina Chiara Garassino et al.
Introduction: Treatment options are limited for patients with advanced NSCLC who progress on anti-programmed cell death-ligand 1 (anti-PD-L1) monotherapy. Second-line platinum-based chemotherapy provides a short progressi...
Durvalumab Consolidation Treatment Following Concurrent Chemoradiotherapy in Limited-Stage SCLC: ADRIATIC China Subgroup Analysis [0.03%]
度伐利尤单抗用于局限期小细胞肺癌同步放化疗后的巩固治疗——ADRIATIC研究中国亚组分析
Lixia Ma,Qiming Wang,Jian Fang et al.
Lixia Ma et al.
Introduction: At the first interim analysis of the phase 3 ADRIATIC trial, durvalumab consolidation significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo in patients with l...
Biomarker Testing Among Patients With Nonsquamous NSCLC Across Three Time Periods and Three Testing Platforms-A Brief Report [0.03%]
基于三个时期的三项检测平台的非鳞状非小细胞肺癌患者的生物标志物检测情况——简报
Zhen Jason Fan,Roxana Tudor,Michael Cabanero et al.
Zhen Jason Fan et al.
Biomarker testing in stage III/IV nonsquamous NSCLC is critical in treatment decision-making. This ambispective review included 1028 patients across three time periods to evaluate the clinical impact of evolving genomic testing platforms. C...
RATIONALE-303: Long-Term Outcomes of Tislelizumab in Previously Treated Advanced/Metastatic NSCLC [0.03%]
特瑞普利单抗治疗既往全身治疗后的晚期或转移性非小细胞肺癌的疗效和安全性：一项随机、双盲、Ⅲ期研究
Pedro de Marchi,Yun Fan,Zhiyong Ma et al.
Pedro de Marchi et al.
Introduction: RATIONALE-303 (NCT03358875) investigated the efficacy and safety of tislelizumab versus docetaxel in pretreated patients with advanced NSCLC. We present long-term outcomes with an additional 30-month follow-...
Concurrent Hypertrophic Osteoarthropathy and Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis in a Patient With NSCLC: A Case Report [0.03%]
一例非小细胞肺癌患者并发肥大性骨关节病和免疫检查点抑制剂诱导的炎症性关节炎：病例报告
Isaac K S Ng,Kaung Myat,Salil B Singbal et al.
Isaac K S Ng et al.
Hypertrophic osteoarthropathy (HOA) is a prototypical paraneoplastic arthritis associated with lung cancer, specifically NSCLC. With the increasing use of immune checkpoint inhibitors (ICIs), ICI-induced inflammatory arthritis (IA) is anoth...
Biopsies Can Predict Lung Adenocarcinoma IASLC Grade: A New Proposal and Grading Pitfalls [0.03%]
活检可以预测肺癌IASLC分级：新建议及评估陷阱
Fang Zhou,Atreyee Basu,Jose G Mantilla et al.
Fang Zhou et al.
Introduction: The International Association for the Study of Lung Cancer grading system for resected invasive lung adenocarcinoma provides robust prognostic stratification for recurrence risk and overall survival. However...